BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. APGE
7. ABBV
8. DFTX
9. USO
10. IBM

Go back to BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)

BioMarin Pharma (BMRN) Misses Q3 EPS by 2c

October 26, 2022 4:04 PM EDT

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $505.3 million versus the consensus estimate of $516.56 million.

GUIDANCE:

BioMarin Pharma sees 2022 revenue of $2.06-2.16 billion, versus the consensus of $2.12... More